Advanced

Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome

Ristiniemi, Noora; Lund, Juha; Tertti, Risto; Christensson, Anders LU ; Ilva, Tuomo; Porela, Pekka; Pulkki, Kari and Pettersson, Kim (2012) In Clinical Biochemistry 45(7-8). p.535-540
Abstract
Objectives: To investigate the predictive value of cystatin C among patients diagnosed with non-ST-elevation acute coronary syndrome (nSTE-ACS). Design and methods: Admission serum samples from 245 nSTE-ACS patients were measured with a novel cystatin C immunoassay based on a dry-reagent, double monoclonal design. Creatinine concentrations, estimated glomerular filtration rates (eGFR) and one-year follow-up data were available for these patients. Results: During the follow-up period, 34 (14%) of patients had myocardial infarction (MI) and 25 (11%) died. Increased serum cystatin C was an independent predictor of all-cause mortality and combined events (all-cause mortality and MI) after adjustment to non-biomarker baseline factors, hazard... (More)
Objectives: To investigate the predictive value of cystatin C among patients diagnosed with non-ST-elevation acute coronary syndrome (nSTE-ACS). Design and methods: Admission serum samples from 245 nSTE-ACS patients were measured with a novel cystatin C immunoassay based on a dry-reagent, double monoclonal design. Creatinine concentrations, estimated glomerular filtration rates (eGFR) and one-year follow-up data were available for these patients. Results: During the follow-up period, 34 (14%) of patients had myocardial infarction (MI) and 25 (11%) died. Increased serum cystatin C was an independent predictor of all-cause mortality and combined events (all-cause mortality and MI) after adjustment to non-biomarker baseline factors, hazard ratio (HR) 2.19 (per increase of 1 tertile; 95% CI 1.28-3.78, p = 0.0046) and 1.75 (1.22-2.51, p = 0.0024), respectively. Corresponding values for eGFR were 2.56 (1.43-4.59, p = 0.0016) and 1.76 (1.23-2.53, p = 0.0022), respectively. Creatinine was not an independent predictor of endpoints (p > 0.05). Conclusions: Cystatin C was associated with an increased risk of death and combined events in patients with nSTE-ACS. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Acute coronary syndrome, Cystatin C, Kidney, Myocardial infarction, Renal insufficiency, Risk
in
Clinical Biochemistry
volume
45
issue
7-8
pages
535 - 540
publisher
Elsevier
external identifiers
  • wos:000303553300005
  • scopus:84860210769
ISSN
1873-2933
DOI
10.1016/j.clinbiochem.2012.02.012
language
English
LU publication?
yes
id
e0f62c23-421b-4037-9cb2-e13e7d15ae27 (old id 2551645)
date added to LUP
2012-06-01 08:49:07
date last changed
2017-10-01 03:21:54
@article{e0f62c23-421b-4037-9cb2-e13e7d15ae27,
  abstract     = {Objectives: To investigate the predictive value of cystatin C among patients diagnosed with non-ST-elevation acute coronary syndrome (nSTE-ACS). Design and methods: Admission serum samples from 245 nSTE-ACS patients were measured with a novel cystatin C immunoassay based on a dry-reagent, double monoclonal design. Creatinine concentrations, estimated glomerular filtration rates (eGFR) and one-year follow-up data were available for these patients. Results: During the follow-up period, 34 (14%) of patients had myocardial infarction (MI) and 25 (11%) died. Increased serum cystatin C was an independent predictor of all-cause mortality and combined events (all-cause mortality and MI) after adjustment to non-biomarker baseline factors, hazard ratio (HR) 2.19 (per increase of 1 tertile; 95% CI 1.28-3.78, p = 0.0046) and 1.75 (1.22-2.51, p = 0.0024), respectively. Corresponding values for eGFR were 2.56 (1.43-4.59, p = 0.0016) and 1.76 (1.23-2.53, p = 0.0022), respectively. Creatinine was not an independent predictor of endpoints (p > 0.05). Conclusions: Cystatin C was associated with an increased risk of death and combined events in patients with nSTE-ACS. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.},
  author       = {Ristiniemi, Noora and Lund, Juha and Tertti, Risto and Christensson, Anders and Ilva, Tuomo and Porela, Pekka and Pulkki, Kari and Pettersson, Kim},
  issn         = {1873-2933},
  keyword      = {Acute coronary syndrome,Cystatin C,Kidney,Myocardial infarction,Renal insufficiency,Risk},
  language     = {eng},
  number       = {7-8},
  pages        = {535--540},
  publisher    = {Elsevier},
  series       = {Clinical Biochemistry},
  title        = {Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome},
  url          = {http://dx.doi.org/10.1016/j.clinbiochem.2012.02.012},
  volume       = {45},
  year         = {2012},
}